Blood test monitoring for early breast cancer recurrence
Treatments studied
Part of Cancer, Skin clinical trials.
This trial uses a blood test to look for tiny bits of tumor DNA after treatment. If found, participants receive new drug combinations to try to prevent cancer from returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of breast cancer called HR-positive/HER2-negative
- You have been on hormone therapy for at least 2 years and plan to continue for 3 more years
- You had surgery to remove the cancer and are cancer-free by scans
- You can provide a tissue sample from your original tumor
- You do not have metastatic (spread) breast cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
This study looks for tiny bits of cancer DNA in your blood after breast cancer surgery. A blood test called NGS may help doctors find early signs of cancer coming back, and you would give samples and have checkups for 3 years.
This study tracks tiny traces of cancer DNA in the blood over time to see if it can find early signs of breast cancer coming back. It looks at different types of breast cancer and at different points in a patient's treatment journey.
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
This trial tests whether a blood test (ctDNA) can help doctors monitor how well chemotherapy before surgery is working in women with HER2-positive breast cancer. It aims to see if changes in the blood can predict treatment success.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.